Lp(a) in the Horizon of Diagnostics and Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms27010290 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Pietro Formisano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Federico II University of Naples, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Lipoprotein(a), Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Milan.
Abstract (Originalsprache)
Low-density lipoprotein cholesterol (LDL-C) has traditionally been the primary biomarker used to assess cardiovascular risk. However, a substantial proportion of cardiovascular events occur in individuals with LDL-C levels within the normal range, highlighting the need for additional risk markers. Lipoprotein(a) [Lp(a)] has emerged as an independent and genetically determined cardiovascular risk factor that is not adequately captured by conventional lipid profiling. Elevated Lp(a) levels are associated with an increased risk of atherosclerotic cardiovascular disease, including coronary artery disease, ischemic stroke, and calcific aortic valve stenosis, and appear to be particularly relevant in the context of premature cardiovascular events. The pathogenicity of Lp(a) is driven by distinct mechanisms that extend beyond cholesterol transport. These include pro-atherogenic, pro-inflammatory, and pro-thrombotic effects mediated largely by oxidized phospholipids carried by the particle and by the structural properties of apolipoprotein(a), which interfere with fibrinolysis. Despite its strong and stable genetic determination, Lp(a) remains underrecognized and inconsistently measured in clinical practice, partly due to historical limitations in assay standardization and reporting. This minireview summarizes current knowledge on the pathophysiological mechanisms underlying elevated Lp(a), discusses its clinical implications for cardiovascular risk assessment, and highlights the importance of standardized Lp(a) measurement in routine practice, particularly in light of emerging Lp(a)-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, Federico II University of Naples, 80131 Naples, Italy.
- Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy.
- Experimental Laboratory for Research on Organ Damage Biomarkers, IRCCS Istituto Auxologico Italiano, 20149 Milan, Italy.
- Department of Experimental Medicine and Biochemical Sciences, University of Perugia, 06132 Perugia, Italy.
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, 86077 Pozzilli, Italy.
- Department of Medicine, University of Udine, 33100 Udine, Italy.
ORCID-Profile: Pietro Formisano, Elena Vianello, Elena Dozio, Lorenza Tacchini, Luigina Romani, Francesco Curcio, Marina Maria Bellet, Massimiliano Marco Corsi-Romanelli
Förderung
- University of Milan
Zitieren
APA
Formisano, P., Vianello, E., Dozio, E., Tacchini, L., Romani, L., Frati, L., Curcio, F., Bellet, M. M., & Corsi-Romanelli, M. M. (2025). Lp(a) in the Horizon of Diagnostics and Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010290
Vancouver
Formisano P, Vianello E, Dozio E, Tacchini L, Romani L, Frati L, et al. Lp(a) in the Horizon of Diagnostics and Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010290
BibTeX
@article{Formisano2025,
author = {Formisano, Pietro and Vianello, Elena and Dozio, Elena and Tacchini, Lorenza and Romani, Luigina and Frati, Luigi and Curcio, Francesco and Bellet, Marina Maria and Corsi-Romanelli, Massimiliano Marco},
title = {Lp(a) in the Horizon of Diagnostics and Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms27010290}
}
EUVIMED